Home>Topics>Stocks>Jazz Pharmaceuticals

Jazz Pharmaceuticals

  1. All
  2. Headlines
  1. Jazz Pharmaceuticals' (JAZZ) CEO Bruce Cozadd on Q2 2014 Results - Earnings Call Transcript


    Tue, 5 Aug 2014

    Jazz Pharmaceuticals , Inc. (NASDAQ: JAZZ ) Q2 2014 Results Earnings Conference Call August 5, 2014, 04:30 PM ET Executives Katherine Littrell

  2. Jazz updates guidance after Q2 results


    Tue, 5 Aug 2014

    Jazz Pharmaceuticals ( JAZZ -1.5% ) Q2 results : Total revenues: $291.2M (+39.8%); Operating Expenses: $216.9M (+65.3%); Operating

  3. CANbridge inks China commercialization deal


    Mon, 28 Jul 2014

    CANbridge Life Sciences enters into an exclusive partnership with Jazz Pharmaceuticals ' (NASDAQ: JAZZ ) EUSA Pharma to commercialize Caphosol in China. Caphosol is an oral electrolyte solution designed to moisten

  4. Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment


    Tue, 8 Jul 2014

    a company director bought 50,000 shares in the high $6 range. This same director bought 50,000 shares of Jazz Pharmaceuticals ( JAZZ ) in 2009 for a price around $9 - she is a long term investor and still owns Jazz shares. The speculation

  5. A Young Power Couple's Kickstart Portfolio


    Fri, 6 Jun 2014

    Corcept Therapeutics CORT 108 0.04 N/A Matt's Roth IRA: Cyberonics CYBX $179 0.07 N/A Matt's Roth IRA: Jazz Pharmaceuticals JAZZ 144 0.05 N/A Matt's Roth IRA: JPMorgan Chase JPM 167 0.06 Matt's Roth IRA: Liberty All Star Equity

  6. Top 5 Rallying Biotech Stocks Being Snapped Up By Insiders


    Mon, 28 Feb 2011

    Application to the FDA for the injection formula of FUSILEV, used to treat colorectal cancer (Jan. 2011). 4. Jazz Pharmaceuticals , Inc. (JAZZ): Market cap of $920.46M. Moving Averages: The stock is currently 4.28% above its 20-day

Content Partners